A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections

Sanyuktha Tulasidas¹
Pooja Rao²
Sevitha Bhat²
Radhakrishna Manipura¹

¹Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, Manipal, India; ²Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal McGill Center for Infectious Diseases, Mangalore, Manipal, India

Introduction: Candida species, one among the opportunistic fungi, has become a common pathogen causing vaginal thrush and nosocomial bloodstream infections (BSIs). This study aims to evaluate the prevalence and antifungal susceptibility of various Candida species and slime production by Candida species in BSIs and vulvovaginal candidiasis (VVC).

Materials and methods: A total of 176 samples were collected for a period of 1 year. Antifungal susceptibility testing and biofilm production testing were performed by the Kirby-Bauer method and crystal violet assay, respectively.

Results: Out of 176 samples, 74 (42%) were from BSIs and 102 (58%) were from VVC. The biofilm production was comparatively high in blood isolates, 55 (74%), than cervical isolates, 45 (44%). Increase in the trends of non-albicans Candida (NAC) species was seen in our setup. Good susceptibility rates were seen among Candida species, 82.38% to voriconazole and an increasing resistance pattern of 26.13% to fluconazole.

Conclusion: Speciation of Candida becomes important as the prevalence of NAC is increasing. Antifungal susceptibility testing by the disk diffusion method is cost effective and should be adopted in routine testing as there is an increasing azole resistance, especially in invasive NAC infections. In this study, there was no correlation of antifungal drugs with the biofilm production.

Keywords: biofilm, Candida, azoles, vulvovaginal, bloodstream infections

Introduction

Candida species are part of the normal flora of healthy individuals and are considered opportunistic pathogens as they colonize different tissues and cause systemic mycosis when the immune system of the host is depressed.¹ Over the last few years, the incidence of fungal infections has progressively raised and it has been a primary cause of morbidity and mortality in immune-compromised and severely ill patients and hence is rightly called the “disease of diseased”.² Vulvovaginal candidiasis (VVC) affects 75% of all women at least once in their lifetime, most commonly during childbearing age.³ Candida species is the fourth most common cause of nosocomial bloodstream infections (BSIs), with a significantly high attributable mortality (49%–70%). The use of central venous catheters has been found to be responsible for >70% of bloodstream and deep-tissue infections.⁴ Candida albicans is the most common fungal isolate recovered from blood in the last few decades.⁵ Infections caused by Candida spp. depend on expression of virulence factors such as germ tube formation, adhesins, phenotypic switching, biofilm formation, and the production of hydrolytic enzymes.⁶

In recent studies, it was found that 80% of human infections result from pathogenic biofilms. Biofilms are group of microorganisms that are embedded in an extracellular
matrix (ECM), forming a complex three-dimensional architecture on biotic and abiotic surfaces. Depending on different sites of infection and environmental cues, quantity and composition of the biofilm vary from one species to another, but \textit{C. albicans} has unique developmental characteristics because of dimorphic switching from a yeast form to a filamentous form. The presence of biofilm provides structural heterogeneity, decreases susceptibility to antimicrobials and biocides, and protects the fungus from host defenses. \textit{Candida} shows resistance to azoles due to widespread and long term use of it, so it is necessary to identify \textit{Candida} species during early infection and monitor their antifungal susceptibility for providing appropriate treatment. Hence, our study evaluates the prevalence, antifungal susceptibility in VVC and bloodstream candidemia (BSC), and also compares the biofilm formation in various \textit{Candida} species.

**Materials and methods**

A 12-month cross-sectional study was conducted in the Department of Microbiology, Kasturba Medical College, Mangalore, India. Patients of all age groups clinically suspected to have candidemia or candida vaginitis have been included in the study. A total of 176 clinical isolates of \textit{Candida} species was obtained. Presumptive identification of \textit{Candida} isolates was done by conventional methods such as colony morphology (white- to cream-colored pasty colonies), Gram staining (Gram-positive budding yeast cells with or without pseudohyphae), germ tube test, and HiCrome agar (M1297A-100G; HiMedia Laboratories, Mumbai, India) microscopic morphology on corn meal agar (Microexpress; Tulip Diagnostics, Mumbai, India). Colonies were identified by their white to cream color pasty appearance, and Gram stain was done to identify and confirm as \textit{Candida}. It was then subcultured onto chrome agar for speciation and incubated at 37\textdegree C for 48 hours. Isolates were then differentiated by the color produced in chrome agar after 48 hours, ie, green – \textit{C. albicans}, blue – \textit{Candida tropicalis}, white – \textit{Candida glabrata}, and pinkish purple – \textit{Candida krusei}. The isolates that were not identified on the chromogenic medium by the color were further identified by microscopic morphological features obtained through slide cultures on corn meal agar incubated at 37\textdegree C for 48 hours. Some of the bloodstream isolates were identified to species level using the VITEK 2 yeast identification system.

**Biofilm formation**

Growth from chocolate agar was taken in 5 mL of sterile brain heart infusion (BHI) broth and incubated overnight. It was followed by a 1:100 dilution in BHI. Then, 100 µL of diluted broth was incubated at 37\textdegree C overnight in commercially available presterilized, polystyrene, round-bottomed, 96-well microtiter plate (Cat no. 2101; Thermo Fischer Scientific, Waltham, MA, USA) for biofilm production. The microtiter plates were washed with distilled water.

**Crystal violet assay**

After washing with distilled water, the microtiter plate was stained with 120 µL of 0.1\% aqueous crystal violet solution (crystal violet, Hi-Cert/ACS-GRM114-10G) and incubated at room temperature for 15 minutes. Each well was washed four times with sterile distilled water, blot dried, immediately de-stained with 125 µL of 95\% methanol, and incubated for 15 minutes at room temperature. After de-staining, 100 µL of de-staining solution was transferred to a new well, and the de-staining solution was measured spectrophotometrically using the ELISA reader at 570 nm. Each sample was run in duplicates. The following were the values for the biofilm formation (OD cutoff value – OD$_c$, average OD of negative control – Avg NC)

$$\text{Avg NC}=0.194, \text{SD}=0.013, \text{OD}_c=\text{Avg NC}+3\times0.013$$

$$\text{OD}_c=0.194+0.039, \text{OD}_c=0.233$$

- OD$_c$ < OD$_c$ ≤ OD$_c$ = non-adherent
- OD$_c$ < OD$_c$ ≤ OD$_c$ = weakly adherent
- OD$_c$ < OD$_c$ ≤ OD$_c$ = moderately adherent
- OD$_c$ < OD$_c$ = strongly adherent

**Antifungal susceptibility test**

It was done by the Kirby-Bauer disk diffusion method, mainly for azoles like fluconazole (25 µg, HiMedia Laboratories) and voriconazole (1 µg; HiMedia Laboratories). It was performed on Mueller-Hinton agar supplemented with 2% glucose and 0.5 g of methylene blue per milliliter for enhancing the definition of growth margins, with zone diameter for fluconazole (25 µg) ≥19 mm – susceptible, 15–18 mm – susceptible and dose dependent, and ≤14 mm – resistant and that for voriconazole (1 µg) ≥17 mm – susceptible, 14–16 mm – susceptible and dose dependent, and ≤13 mm – resistant. Along with these, \textit{C. albicans} ATCC 10231 reference strain was also included in this study. Antifungal susceptibility testing was found to be within satisfactory limits. The study samples were collected from the samples that were received routinely in the laboratory. It was not collected separately for this project; hence, informed consent from the patients was not required, and Institutional Ethics Com-
mittee, Kasturba Medical College, Mangalore, approved to conduct this study.

The data were analyzed using the SPSS system, version 17.0 (SPSS Inc., Chicago, IL, USA), and subjected to the chi-squared test. At 95% CI, \( P<0.05 \) was considered as statistically significant.

**Results**

Of the total 176 clinical isolates of *Candida* species, 74 (42%) were obtained from the blood cultures of patients with candidemia, which comprised *C. tropicalis* (27, 36.4%) followed by *C. krusei* (19, 25.6%), *C. albicans* (15, 20.2%), *Candida parapsilosis* (6, 8.10%), *Candida haemulonii* (4, 5.4%), and *C. glabrata* (3, 4%). In all, 102 (58%) *Candida* species were from women of the reproductive age group diagnosed with VVC involving *C. albicans* (66, 64.7%) followed by *C. tropicalis* (23, 22.5%), *C. glabrata* (10, 9.8%), *C. parapsilosis* (2, 1.9%), and *C. krusei* (1). Among the various *Candida* species isolated, *C. albicans* (64%) was most common in VVC, while *C. tropicalis* (23%) was most common in BSC.

A total of 176 clinical isolates was subjected to biofilm production; among 74 blood culture isolates, 55 (74%) were biofilm producers; strong adherence was seen in *C. haemulonii* (100%), moderate adherence was seen in *C. tropicalis* (22%), and weak adherence was seen in *C. krusei* (21%), equation 1. Among 102 cervical swab isolates, 45 (44.11%) were biofilm producers, whereas *C. tropicalis* (43%) showed strong adherence (Figure 1 and Table 1). The biofilm production was higher in isolates from BSI than those from VVC.

Figure 2 describes that *C. haemulonii* produces strongly adherent biofilm followed by *C. tropicalis*, while *C. albicans* and *C. parapsilosis* produce no biofilm.

Among the 74 (42%) *Candida* species isolated from blood, 49 (66.6%) were susceptible to fluconazole while 25 (33.7%) were resistant and 60 (81.1%) isolates were susceptible and 14 (18.9%) were resistant to voriconazole (Figure 3). In our study, *C. haemulonii* and *C. glabrata* showed increased resistance to fluconazole, while resistance rates to voriconazole were comparatively very less and seen among some strains of *C. parapsilosis* (16.6%) and *C. albicans* (7.1%). Among the species isolated from VVC (102), 81 (79.1%) isolates were susceptible to fluconazole while 21 (20.5%) were resistant and 85 (83.3%) were susceptible and 17 (16.6%) were resistant to voriconazole. *C. glabrata* showed a high resistance to fluconazole (100%) in VVC (Figure 4).

**Discussion**

*Candida*, the opportunistic yeast, has been associated with a wide range of human infections, mortality, and morbidity. The wide spectrum of infections ranges from the superficial skin and its appendages to deep-seated or disseminated candidiasis. During the study period, a total of 176 samples were collected, out of which 74 and 102 isolates were obtained from the BSIs and vulvovaginal infections, respectively.

In the present study, non-*albicans* Candida (NAC) – *C. tropicalis* is the most common pathogen to be isolated from patients with BSIs, which is in contrast to the previous studies by Tan et al and by Golia et al and in line with the study done by Hasan et al and Tellapragada et al. A higher incidence of *C. albicans* among vulvovaginal infection was noted in the present study, which is in line with previous studies. In another study, NAC like *C. glabrata* and *C. tropicalis* showed a high incidence in VVC. However, next commonly isolated species were NAC indicating their emergence. Hence, NAC cannot be ignored either in BSI or VVC because of their high virulence and tolerance to azoles, making it difficult to treat these infec-

**Table 1** Biofilm production in different species of *Candida* in BSI and VVC

<table>
<thead>
<tr>
<th><em>Candida</em> spp.</th>
<th>BSI biofilm producers</th>
<th>VVC biofilm producers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BSI biofilm positive/total</td>
<td>%</td>
</tr>
<tr>
<td><em>C. albicans</em></td>
<td>8/15</td>
<td>53.3</td>
</tr>
<tr>
<td><em>C. haemulonii</em></td>
<td>4/4</td>
<td>50</td>
</tr>
<tr>
<td><em>C. krusei</em></td>
<td>16/19</td>
<td>84.2</td>
</tr>
<tr>
<td><em>C. tropicalis</em></td>
<td>24/27</td>
<td>88.9</td>
</tr>
<tr>
<td><em>C. glabrata</em></td>
<td>1/3</td>
<td>33.3</td>
</tr>
<tr>
<td><em>C. parapsilosis</em></td>
<td>2/6</td>
<td>33.3</td>
</tr>
</tbody>
</table>

**Abbreviations:** BSI, bloodstream infection; *C. albicans*, *Candida albicans*; *C. glabrata*, *Candida glabrata*; *C. haemulonii*, *Candida haemulonii*; *C. krusei*, *Candida krusei*; *C. parapsilosis*, *Candida parapsilosis*; *C. tropicalis*, *Candida tropicalis*; VVC, vulvovaginal candidiasis.
Tulasidas et al

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance  2018:11
submit your manuscript | www.dovepress.com
Dovepress

2446

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Oct-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Biofilm production is considered as one of the most potent pathogenic traits contributing to treatment failures and recurrent infections. Out of 176 Candida isolates, 100 (56.8%) isolates produced biofilm. In the present study, 55 (74%) blood isolates were biofilm positive; strong biofilm production was seen in C. haemulonii from blood, which is in contrast to study done by Tellapragada et al19 and Deorukhkar et al2 where higher biofilm production was seen in C. albicans. In a study done by Shin et al,3 Kaskatepe et al,20 and Tumbarello et al,21 a higher biofilm production was seen in non-C. albicans.

Among 102 cervical isolates, 45 (44%) were biofilm producers. Strong biofilm production was seen in C. tropicalis, which is in contrast to study done by Tellapragada et al19 and Harakuni et al,22,23 where a higher biofilm production was noted in C. albicans.

Figure 2 Comparison of biofilm formation in various Candida spp.
Abbreviations: C. albicans, Candida albicans; C. glabrata, Candida glabrata; C. haemulonii, Candida haemulonii; C. krusei, Candida krusei; C. parapsilosis, Candida parapsilosis; C. tropicalis, Candida tropicalis.

Figure 3 Antifungal susceptibility pattern of azoles in BSI.
Abbreviations: BSI, bloodstream infection; C. albicans, Candida albicans; C. glabrata, Candida glabrata; C. haemulonii, Candida haemulonii; C. krusei, Candida krusei; C. parapsilosis, Candida parapsilosis; C. tropicalis, Candida tropicalis.
The risk factors for candidemia associated with intensive care unit patients subjected to intravenous and central line catheters, total parenteral nutrition, use of multiple antibiotics, previous steroid therapy, post surgery, and an immunocompromised status.24,25

Out of 176 Candida species, 130 (73.86%) were susceptible to fluconazole, while 46 (26.13%) of them were resistant. In all, 145 (82.38%) of isolates were voriconazole susceptible and 31 (17.6%) were resistant. This shows that there is an increase in resistance to fluconazole, which is in line with the previous study.24 The degree of resistance seen is more common with fluconazole as they are being used more commonly as the initial line of treatment and in empirical therapy. Biofilm formation was prominent in blood isolates when compared to cervical isolates, thus indicating it as one of the virulence markers in BSI; the same was observed in a study done by Harakuni et al.22 Seven of 102 (16.8%) isolates showed biofilm production with resistance to both fluconazole and voriconazole; only one out of 102 isolates showed fluconazole resistance, and among blood samples, 13 of 74 (17.5%) isolates showed biofilm production with resistance to fluconazole and voriconazole and six out of 74 (8.1%) isolates showed biofilm production with resistance to fluconazole alone. We observed a higher degree of resistance to fluconazole in biofilm producers as compared to that in non-producers, which has been seen in NAC and reported in other studies.5,20,25 The limitation of this study is that minimum inhibitory concentration for azoles was not performed.

**Conclusion**

Biofilm production and antifungal drug resistance were observed more in non- C. albicans, hence indicating its emergence and an issue of crucial importance in the treatment of immunocompromised individuals. Biofilm production could act as one of the factors in reducing the penetrability of the antifungal agents and also increasing the virulence nature of invasive candidiasis. Antifungal drug resistance was more commonly seen with fluconazole. Hence, voriconazole may be used as the initial line of therapy, especially in NAC isolates. These data of Candida-forming biofilms and antifungal susceptibility become necessary to reduce the net effect of the increasing severity of Candida infections, drug resistance, and economic burden.

**Data availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Acknowledgment**

This study has been supported by Manipal Academy of Higher education, Mangalore, India.

**Author contributions**

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.
References


